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Abstract 
Objective: to compare long-term outcomes following microwave endometrial ablation 
(MEA™) and thermal balloon ablation (TBall). 
   
Design: follow up of a prospective, double blind randomised controlled trial at five years  
 
Setting: teaching hospital in UK 
 
Population: 320 women eligible for and requesting endometrial ablation  
 
Methods:.1. Eligible women were randomised in a 1:1 ratio to undergo microwave or thermal 
balloon ablation. Postal questionnaires were sent to participants at a minimum of five years 
post operatively to determine satisfaction with outcome, menstrual status, bleeding scores 
and quality of life measurement. Subsequent surgery was ascertained from the women and 
the hospital operative database. 
 
Main Outcome Measures: the primary outcome measure was overall satisfaction with 
treatment. Secondary outcomes included evaluation of menstrual loss, change in quality of 
life scores and subsequent surgery  
 
Results: of the women originally randomised 217/314 (69.1%) returned questionnaires. 
Non-responders were assumed to be treatment failures for data analysis.  The primary 
outcome of satisfaction was similar in both groups (58% for MEATM versus 53% for TBall, 
difference 5% (95% CI -6% to 16%)). Amenorrhoea rates were high following both 
techniques (51% versus 45%, difference 6% (95% CI -5% to 17%)). There was no significant 
difference in the hysterectomy rates between the two arms (9% versus 7%, difference 2% 
(95% CI -5% to 9%)). 
 
Conclusions: at five years post treatment there are no significant clinical differences in 
patient satisfaction, menstrual status, quality of life scores or hysterectomy rates between 
MEATM and Thermachoice 3, thermal balloon ablation. 
 
Keywords: Heavy menstrual bleeding, endometrial ablation, randomised controlled trial, 
long term follow up. 
 
Trial registration:- http://controlled-trials.com/ ISRCTN 28184453 
 
Introduction 
Few randomised trials comparing surgical interventions measure follow up of outcomes in 
the long term. This can lead to difficulty in establishing the true impact and worth of an 
intervention. Endometrial ablation is a well-researched treatment for heavy menstrual loss 
and a number of second generation ablative techniques are recommended by NICE for the 
treatment of this complaint.1 Few of the commercially available second generation 
techniques available have been evaluated in independent, adequately powered randomised 
trials with meaningful clinical and economic outcomes. Fewer still have undergone scrutiny 
in the long term.    
 
Both Microwave endometrial ablation (MEA™)2 and Thermal Balloon (TBall)3 endometrial 
ablation are NICE recommended ablative techniques1. Microwave ablation, although 
recently removed from the UK market, has been independently evaluated in randomised 
trials with published follow up data at five4 and ten5 years. This made it the ideal comparator 
for Thermachoice 3™, thermal balloon which required re-evaluation as data in the literature 
pertained to an earlier, perhaps less effective versions of the balloon.3,6 The original results 
from this cohort demonstrated that the microwave technique was quicker to perform and 
required less post-operative analgesia, but clinical outcomes at one year were comparable 
between the two techniques7. Microwave ablation was likely to be more cost effective at one 
year.8 
 
In this paper we will present and discuss the outcomes at five years post treatment. 
 
Methods 
Full methodological and operative details can be found in the original paper.7 The trial 
protocol is held by the funding body:- Chief Scientist Office, Scottish Government Health 
Directorates, ref CZH/4/117 and also by Health Services Research Unit, Aberdeen 
University. Local ethics committee approval was obtained for long-term follow-up at five 
years. Women complaining of heavy menstrual loss that desired and were eligible for 
endometrial ablation were recruited from the gynaecology department of Aberdeen Royal 
Infirmary between January 2003 and January 2005. Eligible patients were pre-menopausal, 
had completed their families, and gave their informed consent to participate within the trial. 
They had a uterine cavity length of < 12 cms,   no histopathological abnormalities of the 
endometrium and fibroids if present were < 3cms and not obstructing the uterine cavity. The 
patients did not routinely undergo hysteroscopy prior to recruitment unless an abnormality 
was identified on transvaginal ultrasound scan. Women with previous caesarean section 
were included if scar thickness was <10mm. 
 Sample size 
The original power study determined that 290 recruits were required to give an 80% power of 
demonstrating a 12% difference in those totally or generally satisfied with treatment. 
Additionally this number gives 80% power to detect a 15% difference in amenorrhoea rates 
(2P<0.05) and 90% power to detect a difference in menstrual scores (pictorial assessment 
blood loss chart, PBLAC) of 10, again with significance at the 5% level.  
Three hundred and twenty recruits were randomised in a ratio of 1:1 to the MEATM and TBall 
arms of the study after obtaining informed consent. Six post randomisation exclusions 
occurred hence 314 women were treated in the trial. The mode of treatment was not 
revealed to the women, or the statistician.  
 
Objective/outcomes 
Postal questionnaires were sent at a minimum of five years after the original procedure. The 
primary objective of this study was to detect any difference in patient satisfaction between 
the two treatments. Secondary outcomes were menstrual status, changes in health-related 
quality of life [Short Form-12 (SF12) and EQ-5D] and any further surgery received. The 
questionnaire was sent to the participant. Those who did not respond were sent a postal 
reminder and, finally, a telephone call to ascertain whether they wished to participate. Data 
were entered into an SPSS (version 16, SPSS Inc., Chicago, IL, USA) database. 
Subsequent operations were established from the questionnaires and from the hospital 
database for all recruited women. 
 
Statistical Analysis 
All statistical analyses were carried out using SPSS v20 (IBM Inc, Armonk, NY, USA) unless 
otherwise stated.  Intention-to-treat analysis was used.  Differences in proportions and 95% 
confidence intervals were calculated in Excel using Newcombe’s method.9 Bleeding scores, 
pain scores and health-related quality of life measures (EQ-5D and SF-12 scores) were 
compared using a linear regression model to estimate the mean difference between groups 
after adjusting for baseline values.10  Changes in quality of life from baseline were compared 
using paired t-tests.  Women who had had a hysterectomy at follow-up were included in all 
comparisons.  Non-responders were assigned a negative response (that is presumed 
dissatisfaction) when calculating proportions for satisfaction with the procedure and 
willingness to recommend to a friend. The CONSORT scheme of reporting was adhered 
to.11,12,13 
 
 Results  
Two hundred and seventeen of the 314 (69.1%) women originally randomised returned 
completed questionnaires. The baseline characteristics of the 217 women successfully 
followed up were very similar to those of the total trial group and not statistically significantly 
different between either.  Mean age at follow up was 48 (SD 5.2) in both arms. The flow of 
participants through the trial is outlined in figure 1. 
 
Participants 
Baseline characteristics of those returning questionnaires at five years are shown in Table 1 
and are comparable 
 
There were no statistically significant differences between the two groups with respect to 
menstrual symptoms (Table 2). This was also the case for the number of women totally or 
generally satisfied with treatment   MEA™  91/157 (58.0%) and TBall 83/157  (52.9%); 
difference (95% CI) 5.1  (-5.9, 16.1) and those who would recommend the treatment to a 
friend, MEA™ 104/157 (66.2%), TBall 89 /157 (56.7%); difference (95% CI) 9.6  (-1.2, 20.3)  
 
 
The amenorrhoea rates are high and comparable for both modalities for those returning 
questionnaires. Even if all non-responders are assumed to be failures and still bleeding 
(except for non-responders known to have had a hysterectomy), then this gives intention to 
treat amenorrhoea rates of 51% (80/157) for MEATM and 45% (70/157) for TBall (risk 
difference 6.4%, 95% CI: -4.7% to 17.4%). 
 
There were no significant differences in quality of life (mean (SD)between groups for SF-12 
(physical functioning) - MEA™ 51.1% (10.1),TBall 52.6 %(8.6); difference (95% CI -0.9 (-3.4, 
1.6), SF-12 (mental functioning) -  MEA™49.1%(9.4),TBall 49.4 %(10.1); difference (95% CI 
0.2 ((-2.4, 2.8) or EQ-5D - MEA™ 0.83 (0.26),TBall 0.83 (0.26); difference (95% CI) 0.01 (-
0.06, 0.07).  SF12 demonstrated significant improvement from the baseline quality of life 
scores for both categories (p<0.01 for both physical and mental functioning) and this was not 
altered significantly from the 12-month follow-up (figure 2 ).   
Subsequent treatment received or continued at five years 
At a minimum of five years following treatment, the majority of women had not required 
further gynaecological surgery. There was no statistically significant difference in women 
undergoing hysterectomy, with ten women (8.8%) in the MEA™ arm and seven (6.8%) in the 
TBall (difference of 2.0%, 95% CI: -5.1% to 9.1%). Following MEA™, of the ten 
hysterectomies, four were for heavy bleeding, one for cyclical pain, four for pain and 
bleeding and one for prolapse In the TBall arm, one hysterectomy was for pain alone, one 
for heavy bleeding, four for combined pain and bleeding and one for fibroid pressure 
symptoms. There was one repeat ablation in the TBall arm and none in the MEATM arm. 
 
 
Discussion  
Main Findings: The two trial arms remained balanced at the five year follow-up despite the 
dropout of recruits. Those women who did not respond were analysed as treatment failures 
for the principal outcome measure which gives the impression of deterioration in satisfaction 
with treatment over time. Whilst this is the accepted method of analysis it does not lend itself 
to comparison with results from other trials that have not used this method.  
 
It is more likely however given the low hysterectomy rates that satisfaction rates are higher 
and are likely to lie between the rates ascertained by ITT analysis and rates reported by 
responders (totally or generally satisfied, 91/111, 82%, for MEATM versus 83/99, 84%, for 
TBall). The same argument also applies to amenorrhoea rates which by ITT analysis, for 
MEATM, assuming all non-responders are still bleeding is 51%, but 68% for responders. For 
TBall the corresponding rates are 45% and 61%. 
Whilst no statistically significant differences could be demonstrated between the two 
treatments it is important to point out that with only 219 responders there was not adequate 
power to detect smaller perhaps meaningful differences in clinical outcomes between the 
two ablative techniques. Given that hysterectomy rates were low and comparable it does 
support the fact that there is little difference in outcome in the long term. Subsequent 
operations were determined not only from the patient questionnaire but also from the 
hospital database. As fewer than 10% of women had left the region and this is the only 
hospital supplying gynaecological care, it is likely that these figures are representative of the 
original recruited cohort. Hysterectomy rates of around 16% have been previously reported 
for follow up after five years for MEATM.5 
 
Women recruited had a subjective complaint of heavy bleeding and formal menstrual blood 
loss measurements were not performed. The majority of woman had a preoperative 
ultrasound and endometrial biopsy but hysteroscopy was not performed preoperatively 
unless clinically indicated. All cases underwent hysteroscopy immediately prior to insertion of 
the ablative device to ensure no false passage or perforation. This mirrors recommended 
clinical practice, thereby increasing the generalisibility of the results. Also, the procedures 
were all undertaken by a trainee and not a consultant hysteroscopic surgeon with extensive 
experience of both techniques. It is important to reiterate that during the treatment phase 
with the thermal balloon that the pressure was maintained at between 160 -180 mmHg by 
injecting further dextrose solution during the treatment phase. This, along with the active 
impellor in Thermachoice 3™, circulating the heated fluid, may account for the better results 
achieved by the balloon in this study when compared to previous trials. 
 
Heavy menstrual loss is known to cause significant deterioration in quality of life, and SF-12 
and EQ-5D were used although neither has been formally validated for menstrual disorders. 
Neither is a condition specific QOL tool but SF-36 has been used in the past to demonstrate 
reduction in generic QOL values for menorrhagia14 and also shown return to normative 
values following endometrial ablation for heavy menstrual loss.3,15 Importantly normative 
values for the healthy female population are known for SF-12.16 EQ-5D is used for economic 
calculations which were not repeated at five year follow up. The physical component of the 
SF-12 score demonstrated improved scores from baseline for responders and maintained at 
normative levels. The mental component followed a similar pattern, with an overall 
improvement for both arms at 12 months, maintained at the normative values (49.2) by five 
years. Importantly, no significant difference was noted between the groups. 
 
Strengths and Limitations 
The strength of this trial is that it was an independent, government funded, double blind 
randomised controlled trial and hence bias is minimised. The procedures were performed on 
patients with a generic complaint of heavy menstrual loss where the patients had decided 
upon endometrial ablation as treatment. It is entirely possible that some would not have true 
menorrhagia, but this reflects standard practice in the UK and through randomisation 
prognostic factors should be equalised. There were limited pre-selection criteria with cavities 
up to 12 cms treated and no exclusion of smaller fibroids which enhances generalisibility as 
does the fact that the procedures were all performed by a trainee. 
 
It is unfortunate that the numbers returning questionnaires failed to meet the original power 
study requirements, but the number of hysterectomies performed at five years was 
comparable and low at under 10% in each arm, which is reassuring. An operating pressure 
of between 160 and 180mmHg was maintained throughout the TBall treatment phase which 
was not the manufacturer’s recommendation. A failure to do this may lead to inferior results 
 
Long-term follow up of interventional randomised trials are rare but offer invaluable 
information for the health care purchaser and potential patient. Five year follow up data are 
available for Novasure6, Microwave ablation4 and now Thermachoice 3 and are highly 
informative, particularly as health related quality of life data are also available in addition to 
menstrual outcomes. Ten year data are also available for transcervical resection of the 
endometrium, microwave ablation5 and Novasure17, and whilst it is commendable that these 
data are available, it perhaps offers principally reassurance of endometrial ablation’s long 
term safety and efficacy rather than the ability to discriminate between different techniques. 
This is because almost 50% of the recruits from the trials are menopausal by this stage, 
making menstrual status a meaningless outcome18, and almost all repeat surgeries, 
including hysterectomies for treatment failure occur within the first three years of endometrial 
ablation.19  
 
Interpretation  
This trial confirms that Thermachoice 3™ achieves better results than earlier models of this 
balloon device2,6. It is simple to use requiring minimal dilatation of the cervix and has been 
successfully used under local anaesthetic. Whilst treatment times are slower than MEATM 
and short term costs slightly higher, clinical and QOL outcomes are comparable with low 
hysterectomy rates. These results should be used and quoted when critically assessing 
Thermachoice 3™ rather than trials involving previous models which are now obsolete 
 
Conclusion  
This trial confirms that Thermachoice 3™ endometrial ablation achieves comparable long-
term results to Microwave Endometrial Ablation, which is one of the most robustly evaluated 
second generation devices. Since MEATM has been removed from the market in the UK by a 
competing company, who purchased the distribution rights, it is important to prove that 
another method of ablation achieves encouraging long term results. These results enhance 
choice for the gynaecologist and reduce the likelihood of a monopoly situation arising for the 
supply of endometrial ablation technology. 
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